Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

David E. Nix; Anup K. Majumdar; Mark J. DiNubile

doi:10.1093/jac/dkh205

Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

David E. Nix, Anup K. Majumdar, Mark J. DiNubile

Research output: Contribution to journal › Review article › peer-review

110 Scopus citations

Abstract

Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

Original language	English (US)
Pages (from-to)	ii23-ii28
Journal	Journal of Antimicrobial Chemotherapy
Volume	53
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1093/jac/dkh205
State	Published - Jun 2004

Keywords

Carbapenems
Distribution
Excretion
Metabolism
Protein binding
Renal insufficiency

ASJC Scopus subject areas

Pharmacology
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1093/jac/dkh205

Cite this

@article{d89c57fef6d549bd883398d47292c5ed,

title = "Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians",

abstract = "Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC",

keywords = "Carbapenems, Distribution, Excretion, Metabolism, Protein binding, Renal insufficiency",

author = "Nix, {David E.} and Majumdar, {Anup K.} and DiNubile, {Mark J.}",

year = "2004",

month = jun,

doi = "10.1093/jac/dkh205",

language = "English (US)",

volume = "53",

pages = "ii23--ii28",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of ertapenem

T2 - An overview for clinicians

AU - Nix, David E.

AU - Majumdar, Anup K.

AU - DiNubile, Mark J.

PY - 2004/6

Y1 - 2004/6

N2 - Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

AB - Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected. JAC

KW - Carbapenems

KW - Distribution

KW - Excretion

KW - Metabolism

KW - Protein binding

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=3042637085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042637085&partnerID=8YFLogxK

U2 - 10.1093/jac/dkh205

DO - 10.1093/jac/dkh205

M3 - Review article

C2 - 15150180

AN - SCOPUS:3042637085

SN - 0305-7453

VL - 53

SP - ii23-ii28

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - SUPPL. 2

ER -

Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this